401811-78-7

Basic information

• Product Name: 5-BROMO-1,3-BENZODIOXOL-4-AMINE
• Synonyms: 5-BROMO-1,3-BENZODIOXOL-4-AMINE;5-Bromobenzo[d][1,3]dioxol-4-amine
• CAS NO: 401811-78-7
• Molecular Formula: C7H6BrNO2
• Molecular Weight: 216.03204
• Mol File: 401811-78-7.mol

Chemical Properties

• Boiling Point: 292.2±40.0 °C(Predicted)
• Appearance: /
• Density: 1.814±0.06 g/cm3(Predicted)
• PKA: 2.06±0.20(Predicted)
• CAS DataBase Reference: 5-BROMO-1,3-BENZODIOXOL-4-AMINE(CAS DataBase Reference)
• NIST Chemistry Reference: 5-BROMO-1,3-BENZODIOXOL-4-AMINE(401811-78-7)
• EPA Substance Registry System: 5-BROMO-1,3-BENZODIOXOL-4-AMINE(401811-78-7)

Safety Data

• Hazardous Substances Data: 401811-78-7(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
5-Bromo-1,3-benzodioxol-4-amine is used as a key intermediate in organic synthesis for the production of various chemical compounds. Its unique structure and functional groups facilitate its incorporation into complex organic molecules, enhancing the diversity and functionality of synthesized products.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, 5-Bromo-1,3-benzodioxol-4-amine is used as a building block for the development of pharmaceutical drugs. Its chemical properties allow it to be a component of drug molecules, potentially contributing to the discovery of new therapeutic agents with novel mechanisms of action.
Used in Pharmaceutical Drug Development:
5-Bromo-1,3-benzodioxol-4-amine is utilized as a precursor in the synthesis of biologically active molecules with potential pharmaceutical applications. Its presence in drug molecules can influence their pharmacological properties, such as potency, selectivity, and pharmacokinetics, thereby contributing to the advancement of new treatments for various diseases.
Used in Research and Development:
5-BROMO-1,3-BENZODIOXOL-4-AMINE is also used in research and development settings to explore its chemical reactivity and potential interactions with other molecules. Understanding its behavior in different chemical environments can lead to the discovery of new applications and uses in various industries.
Used in Chemical Industry:
5-Bromo-1,3-benzodioxol-4-amine finds applications in the chemical industry for the production of specialty chemicals and materials. Its unique structure and properties can be leveraged to create new products with specific characteristics, such as improved stability, reactivity, or selectivity in various chemical processes.

Upstream product

• 72744-56-0 5-bromobenzo[d][1,3]dioxole-4-carboxylic acid 
• 2635-13-4 1,2-(methylenedioxy)-4-bromobenzene 
• 401811-77-6 N-(5-bromo-1,3-benzodioxol-4-yl)carbamic acid 1,1-dimethylethyl ester 

Relevant articles and documents

Pd-tBuONO Cocatalyzed Aerobic Indole Synthesis

A Pd-tBuONO co-catalyzed scalable and practical synthesis of indoles with molecular oxygen as terminal oxidant is developed. Either terminal or internal 2-vinylanilines could be smoothly converted to desired indoles under one general condition. This method has been evaluated in the large scale synthesis of indomethacin and a potential anti-breast cancer drug candidate 1. (Figure presented.).

Discovery of a New Class of Anilinoquinazoline Inhibitors with High Affinity and Specificity for the Tyrosine Kinase Domain of c-Src

Deregulated activity of the nonreceptor tyrosine kinase c-Src is believed to result in signal transduction, cytoskeletal and adhesion changes, ultimately promoting a tumor-invasive phenotype. We report here the discovery of a new class of anilinoquinazoline inhibitors with high affinity and specificity for the tyrosine kinase domain of the c-Src enzyme. Special attention was directed toward finding inhibitors selective against KDR tyrosine kinase in order to ensure that the in vivo profile of a specific Src inhibitor could be determined. The 4-aminobenzodioxole quinazoline series gave compounds with excellent potency and selectivity. The most interesting compounds were evaluated in vivo and displayed good pharmacokinetics following oral dosing. Compounds such as the aminobenzodioxoles were shown to be potent inhibitors of tumor growth in a c-Src-transformed 3T3 xenograft model in vivo, resulting in more than 90% growth inhibition at doses as low as 6 mg/kg po once daily. Src tyrosine kinase inhibitors such as these may provide a novel therapeutic modality for targeting cancer invasion and metastasis.